Table 3 Laboratory Adverse Experience Summary During the Active-Comparator Period (Weeks 6–52)
| Â | Etoricoxib 30 mg | Etoricoxib 60 mg | Etoricoxib 90 mg | Diclofenac 150 mg |
|---|---|---|---|---|
| Â | (N = 197) | (N = 101) | (N = 146) | (N = 102) |
| Â | n (%) | n (%) | n (%) | n (%) |
Laboratory AEs | Â | Â | Â | Â |
   Patients with one or more laboratory AEs | 11 (5.6) | 5 (5.0) | 14 (9.6) | 19 (18.6) |
   With drug-related adverse experiences†| 4 (2.0) | 0 (0.0) | 6 (4.1) | 12 (11.8) |
   With serious adverse experiences | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
   Discontinued due to laboratory AEs | 1 (0.5) | 0 (0.0) | 1 (0.7) | 5 (4.9) |
Laboratory AEs of special interest | Â | Â | Â | Â |
   Alanine Aminotransferase Increased (ALT) | 3 (1.5) | 1 (1.0) | 3 (2.1) | 11 (10.8) |
   Aspartate Aminotransferase Increased (AST) | 2 (1.0) | 1 (1.0) | 2 (1.4) | 11 (10.8) |
   Hemoglobin Decreased | 1 (0.5) | 0 (0.0) | 1 (0.7) | 3 (2.9) |
   Hematocrit Decreased | 1 (0.5) | 0 (0.0) | 1 (0.7) | 1 (1.0) |
   Serum Creatinine Increased | 1 (0.5) | 1 (1.0) | 2 (1.4) | 2 (2.0) |